炎症微环境的作用:对提高乳腺癌纳米靶向治疗的潜在影响。
Role of inflammatory microenvironment: potential implications for improved breast cancer nano-targeted therapy.
机构信息
College of Pharmacy, Jinan University, Guangzhou, 510632, China.
Guang an'men Hospital China Academy of Chinese Medical Sciences, Beijing, China.
出版信息
Cell Mol Life Sci. 2021 Mar;78(5):2105-2129. doi: 10.1007/s00018-020-03696-4. Epub 2021 Jan 2.
Tumor cells, inflammatory cells and chemical factors work together to mediate complex signaling networks, which forms inflammatory tumor microenvironment (TME). The development of breast cancer is closely related to the functional activities of TME. This review introduces the origins of cancer-related chronic inflammation and the main constituents of inflammatory microenvironment. Inflammatory microenvironment plays an important role in breast cancer growth, metastasis, drug resistance and angiogenesis through multifactorial mechanisms. It is suggested that inflammatory microenvironment contributes to providing possible mechanisms of drug action and modes of drug transport for anti-cancer treatment. Nano-drug delivery system (NDDS) becomes a popular topic for optimizing the design of tumor targeting drugs. It is seen that with the development of therapeutic approaches, NDDS can be used to achieve drug-targeted delivery well across the biological barriers and into cells, resulting in superior bioavailability, drug dose reduction as well as off-target side effect elimination. This paper focuses on the review of modulation mechanisms of inflammatory microenvironment and combination with nano-targeted therapeutic strategies, providing a comprehensive basis for further research on breast cancer prevention and control.
肿瘤细胞、炎症细胞和化学因子共同作用,介导复杂的信号转导网络,形成炎症性肿瘤微环境(TME)。乳腺癌的发生发展与 TME 的功能活动密切相关。本文介绍了癌症相关慢性炎症的起源和炎症微环境的主要组成部分。炎症微环境通过多因素机制在乳腺癌的生长、转移、耐药和血管生成中发挥重要作用。提示炎症微环境可能为抗癌治疗提供药物作用机制和药物转运方式的可能性。纳米药物递送系统(NDDS)成为优化肿瘤靶向药物设计的热门话题。可以看出,随着治疗方法的发展,NDDS 可以用于有效地穿越生物屏障并进入细胞,实现药物的靶向递送,从而提高生物利用度、减少药物剂量以及消除非靶向副作用。本文重点综述了炎症微环境的调节机制,并与纳米靶向治疗策略相结合,为进一步研究乳腺癌的防治提供了全面的基础。
相似文献
Eur J Pharm Biopharm. 2021-9
Cancer Biol Med. 2024-6-25
Nanomedicine (Lond). 2019-7-12
引用本文的文献
Ann Med Surg (Lond). 2025-4-10
Naunyn Schmiedebergs Arch Pharmacol. 2025-4-9
Cell Commun Signal. 2024-11-15
Am J Cancer Res. 2022-9-15
Bioengineered. 2022-4
本文引用的文献
Pathol Res Pract. 2020-5
Nat Rev Mol Cell Biol. 2020-3-6
Nat Rev Cancer. 2020-1-24
Int J Mol Sci. 2019-12-5